STINGRAY NANOANTIBODIES FOR NEW GENERATION THERAPEUTIC ANTIBODIES AND NOVEL IMMUNODIAGNOSTICS
by Kamala Bharathi R
Affigenix Biosolutions Private Limited
THE FACT Development of rapid, accurate & low cost point of care diagnostic & therapeutic antibodies are of utmost importance in developing countries to reduce mortality and morbidity. But, the conventional rabbit/ mouse IgG antibody based in vitro diagnostic (IVD) kits & therapeutics has major disadvantages. OUT OF THE BOX SOLUTION
Tapping the marine genomic resources to build a phage displayed stingray single domain antibody (12-15 kDa) library which can be a universal source of nanoantibody against any target of interest.
TYPICAL ANTIBODY
Not suitable for use without refrigeration Not stable in detergents and in high concentrations of urea Molecular weight - 150 kDa Poor tissue penetration Manufacturing- expensive Highly lipophilic-not so soluble in water Cannot survive in gut to make any oral drug
NANOANTIBODY
Survive 90°C (194°F) Stable towards detergents and high concentrations of urea Molecular weight - 12–15 kDa Better permeability in tissues Manufacturing- cheaper & faster Less lipophilic- more soluble in water Active in the intestine after oral application
Acknowledgement: Dr. Muruganandam A, MD & CSO, Affigenix Biosolutions Pvt. Ltd. Ms. Kamala Bharathi R, B.Tech Biotech, Scientist, Contact details: Ph: 9443889546, kamalabharathi@affigenix.com